TSPO显像指导下的恶性胶质瘤患者免疫抑制性髓系肿瘤微环境特征分析
研究纳入9例胶质瘤患者的混合队列,评估[18F]DPA-714(TSPO)PET-MRI对免疫抑制性肿瘤微环境的成像能力,并与影像引导活检的免疫表型分析交叉验证。结果显示[18F]DPA-714摄取与胶质瘤相关髓系细胞数量和活化水平强相关(r=0.84,P=0.009),TSPO表达主要限于HLA-DR+活化的髓系细胞。
要点
- [18F]DPA-714摄取与胶质瘤相关髓系细胞数量及活化水平强相关(r=0.84,P=0.009)。
- TSPO表达主要限于HLA-DR+活化的胶质瘤相关髓系细胞,尤其是浸润的HLA-DR+髓源性抑制细胞和肿瘤相关巨噬细胞。
- [18F]DPA-714阳性组织体积超过[18F]FET阳性体积,且空间分布存在差异。
核心结论
- [18F]DPA-714-PET可用于无创活体成像胶质瘤相关免疫抑制性肿瘤微环境,并可能有助于表征不同疾病阶段髓系细胞浸润程度的肿瘤微环境异质性,也可能促进针对髓系来源肿瘤微环境的新型影像引导疗法开发。
研究设计与样本
- 研究纳入9例胶质瘤患者的混合队列,行[18F]DPA-714-PET-MRI及[18F]FET-PET-MRI检查。
- 对影像引导活检样本行多参数流式细胞术和免疫组织化学免疫表型分析。
- 进行体外放射自显影以验证影像并评估示踪剂结合特异性。
主要发现
- [18F]DPA-714摄取与胶质瘤相关髓系细胞数量和活化水平呈强相关(r=0.84,P=0.009)。
- TSPO表达主要限于HLA-DR+活化的胶质瘤相关髓系细胞,尤其是肿瘤浸润的HLA-DR+髓源性抑制细胞和肿瘤相关巨噬细胞。
- [18F]DPA-714阳性组织体积超过[18F]FET阳性体积,且两者空间分布存在差异。
临床怎么用
- [18F]DPA-714-PET可能用于无创活体成像胶质瘤相关免疫抑制性肿瘤微环境。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumor-associated microglia and macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) are potent immunosuppressors in the glioma tumor microenvironment (TME). Their infiltration is associated with tumor grade, progression, and therapy resistance. Specific tools for image-guided analysis of spatiotemporal changes in the immunosuppressive myeloid tumor compartments are missing. We aimed (i) to evaluate the role of fluorodeoxyglucose (18F)DPA-714* (translocator protein [TSPO]) PET-MRI in the assessment of the immunosuppressive TME in glioma patients, and (ii) to cross-correlate imaging findings with in-depth immunophenotyping. METHODS: To characterize the glioma TME, a mixed collective of 9 glioma patients underwent [18F]DPA-714-PET-MRI in addition to [18F]fluoro-ethyl-tyrosine (FET)-PET-MRI. Image-guided biopsy samples were immunophenotyped by multiparametric flow cytometry and immunohistochemistry. In vitro autoradiography was performed for image validation and assessment of tracer binding specificity. RESULTS: We found a strong relationship (r = 0.84, P = 0.009) between the [18F]DPA-714 uptake and the number and activation level of glioma-associated myeloid cells (GAMs). TSPO expression was mainly restricted to human leukocyte antigen D related-positive (HLA-DR+) activated GAMs, particularly to tumor-infiltrating HLA-DR+ MDSCs and TAMs. [18F]DPA-714-positive tissue volumes exceeded [18F]FET-positive volumes and showed a differential spatial distribution. CONCLUSION: [18F]DPA-714-PET may be used to non-invasively image the glioma-associated immunosuppressive TME in vivo. This imaging paradigm may also help to characterize the heterogeneity of the glioma TME with respect to the degree of myeloid cell infiltration at various disease stages. [18F]DPA-714 may also facilitate the development of new image-guided therapies targeting the myeloid-derived TME.
引用
- Zinnhardt B, Müther M, Roll W, et al. TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma. Neuro Oncol. 2020. PMID: 32047908. doi:10.1093/neuonc/noaa023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。